There are 2789 resources available
Melanoma and other skin tumours
Presenter: Omid Hamid
Session: Expert selection 2
Resources:
Slides
Webcast
Introduction by the Chair
Presenter: Jordi Rodon
Session: Keynote lecture: Drug development: How can academia and industry work together
Resources:
Slides
Webcast
Drug development: How can academia and industry work together
Presenter: Jean-Charles Soria
Session: Keynote lecture: Drug development: How can academia and industry work together
Resources:
Slides
Webcast
LBA16 - KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Presenter: Hope Rugo
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA17_PR - Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Presenter: Gabriel Hortobagyi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA28 - STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC)
Presenter: Janet Brown
Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Resources:
Abstract
Slides
Webcast
LBA29 - Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Presenter: Naveen Vasudev
Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Resources:
Abstract
Slides
Webcast
653O - Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
Presenter: Toni Choueiri
Session: Proffered Paper session - Genitourinary tumours, non-prostate 2
Resources:
Abstract
Slides
Webcast
340O - Radiotherapy is associated with deletion signatures that contribute to poor survival outcomes in cancer patients
Presenter: Emre Kocakavuk
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast
341O - A phase 0 ‘Trigger’ trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma
Presenter: Nader Sanai
Session: Proffered Paper session - CNS tumours
Resources:
Abstract
Slides
Webcast